Overview

LY3214996 +/- HCQ in Pancreatic Cancer

Status:
Recruiting

Trial end date:
2022-09-19

Target enrollment:

Participant gender:

Summary

This study is evaluating the safety and efficacy of combining the study drug LY3214996 with hydroxychloroquine sulfate (HCQ) in patients with advanced pancreatic cancer.

Phase:

Phase 2

Details

Lead Sponsor:

Brian Wolpin, MD, MPH
Kimberly Perez

Collaborator:

Eli Lilly and Company

Treatments:

Hydroxychloroquine